BLPH:NSD-Bellerophon Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 4.09

Change

-0.24 (-5.54)%

Market Cap

USD 0.04B

Volume

0.06M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-06-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-3.28 (-1.62%)

USD81.30B 135.70 104.16
REGN Regeneron Pharmaceuticals, Inc

+1.91 (+0.36%)

USD57.11B 15.26 11.77
BNTX BioNTech SE

-1.78 (-0.83%)

USD49.23B -99,999.99 35.63
VRTX Vertex Pharmaceuticals Incorpo..

-0.51 (-0.27%)

USD48.76B 17.95 12.38
ALXN Alexion Pharmaceuticals, Inc

+0.72 (+0.40%)

USD39.91B 58.41 42.10
BGNE BeiGene, Ltd

-7.33 (-2.23%)

USD30.29B N/A N/A
GMAB Genmab A/S

-0.61 (-1.40%)

USD29.17B 26.59 3.71
SGEN Seagen Inc

+2.93 (+1.91%)

USD27.46B 42.22 39.29
RPRX Royalty Pharma plc

-0.11 (-0.25%)

USD26.79B 22.60 15.62
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BLPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.68% 10% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.68% 10% F 5% F
Trailing 12 Months  
Capital Gain -69.20% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -69.20% 4% F 2% F
Trailing 5 Years  
Capital Gain 110.82% 70% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 110.82% 70% C- 68% D+
Average Annual (5 Year Horizon)  
Capital Gain 455.88% 98% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 455.88% 98% A+ 98% A+
Risk Return Profile  
Volatility (Standard Deviation) 822.50% 3% F 2% F
Risk Adjusted Return 55.43% 81% B- 74% C
Market Capitalization 0.04B 4% F 8% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.29 53% F 83% B
Price/Book Ratio 1.30 93% A 79% C+
Price / Cash Flow Ratio -2.07 16% F 60% D-
EV/EBITDA 0.01 96% A 99% A+
Management Effectiveness  
Return on Equity -142.99% 15% F 7% F
Return on Invested Capital -115.44% 14% F 6% F
Return on Assets -51.86% 12% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.31 56% F 37% F
Short Percent 2.57% 80% B- 59% F
Beta -0.58 98% A+ 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.